# Intranasal CBD Nanocarriers for Dravet and Lennox Gastaut Syndromes > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ced-intranasal-cbd-nanocarriers-for-dra-2026-09-21/ > **Published:** 2026-09-21T15:49:42-04:00 | **Last Modified / Clinically Audited:** 2026-10-01T12:33:19-04:00 > **Clinical Summary:** medical cannabis research: Physician review of Nanostructured lipid carriers for intranasal cannabidiol delivery in Dravet and Lennox-Gastaut syndromes: brid... --- CED Clinical Relevance #88 Verified Clinical Evidence Primary literature analysis of Nanostructured lipid carriers for intranasal cannabidiol delivery in Dravet and Lennox-Gastaut syndromes: bridging preclinical promise to clinical translation. Clinical Insight | CED Clinic This paper is best read as a translational roadmap, not evidence that an intranasal CBD product is ready for children with Dravet syndrome or Lennox Gastaut syndrome. The core clinical problem is real: oral prescription CBD can reduce seizures in these syndromes, yet it has delayed absorption, variable exposure, gastrointestinal adverse effects, liver enzyme concerns, and meaningful interactions with clobazam and valproate. Nanostructured lipid carriers may improve nose-to-brain transport and reduce systemic exposure, but the review identifies the major missing steps: pediatric nasal safety, disease-specific models, pharmacokinetics, dose conversion, device reliability, and randomized clinical trials. Clinical SciencePeer-ReviewedDosing ContextSafety SignalsPhysician Insight AudiencePatients, clinicians, healthcare providers, researchers, and policy analysts. Primary TopicClinical study review: Intranasal CBD Nanocarriers for Dravet and Lennox . Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42751849/) A new review argues that intranasal nanostructured lipid CBD could improve brain delivery for severe childhood epilepsies, but human pediatric safety, dosing, and efficacy data remain absent. What This Study Teaches Us This narrative review searched PubMed, Scopus, Web of Science, and Google Scholar through March 2026 and found preclinical support for intranasal nanostructured lipid CBD improving brain targeting and seizure protection in animal models. It reports 0 completed pediatric DS or LGS clinical trials of intranasal NLC-CBD, 0 human seizure endpoint estimates, and 0 risk ratios for efficacy or safety. Why This Matters For patient care, the paper highlights a plausible way to address oral CBD limitations, including slow onset, low bioavailability, and systemic interactions. For harm reduction, it also makes clear that formulation promise should not be confused with validated pediatric dosing or proven emergency seizure control. Study SnapshotPost TypePhysician-Guided Clinical Science Deep DivePrimary SourceTherapeutic deliveryPublication Date2026Sep17Evidence LevelJournal Article, ReviewFocus AreaIntranasal CBD Nanocarriers for Dravet and Lennox Gastaut SyLead AuthorsYashika, Sachin Yadav, Anish Arora, Nisha Bharti et al.DOI10.1080/20415990.2026.2731738PMIDPMID: 42751849 Clinical Bottom Line This study review translates complex data into practical clinical insights, maintaining realistic therapeutic expectations. Headline vs. Reality Truth Meter | Clinical Analysis **Mainstream Media Claim:** A CBD nose spray could soon deliver faster seizure control for children with Dravet syndrome and Lennox Gastaut syndrome. **Primary Journal Data:** The article is a narrative review of preclinical and formulation literature, not a completed human trial. It reports that intranasal nanostructured lipid CBD has shown higher brain targeting and anticonvulsant signals in animal seizure models, including pentylenetetrazol models, but it provides no pediatric DS or LGS efficacy trial, no seizure reduction percentage in humans, no risk ratio, and no approved dosing regimen. **Dr. Caplan’s Clinical Verdict:** Promising delivery science, but not yet a clinical treatment. Families should not substitute experimental intranasal CBD formulations for prescribed antiseizure therapy outside a regulated trial and specialist supervision. Primary Analysis | Nanostructured lipid carriers for intran **Study Overview:** Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are severe developmental epileptic encephalopathies that appear in early childhood, are unresponsive to medications, and have a dismal neurodevelopmental prognosis. Most patients do not respond well to polytherapy, and the need to fulfill this gap in clinical practice is urgent. Cannabidiol (CBD) has proven to be an effective adjunct drug, but oral preparations have low bioavailability, slow onset and systemic adverse effects. Nanostructured lipid carriers (NLCs) are an innovative therapeutic technology that can deliver CBD directly to the brain via the nose, enhance brain targeting, achieve faster onset, and minimize systemic exposure, which could be a valuable solution to current deficiencies in treatment. Intranasal NLC-CBD has preclinical evidence of increasing brain CBD levels, facilitating anticonvulsant action, and protecting against seizures in established animal models, like pentylenetetrazol-induced convulsions. NLC-based preparations have increased brain-to-plasma ratios and longer central exposure at lower doses in comparison to free or orally administered CBD. Despite these promising findings, there are still translational gaps to be addressed, such as insufficient safety data in the long term, disease-specific DS/LGS genetic models, inconsistencies in the pediatric nasal physiology, and conventional clinical dosing paradigms. Literature for this review was identified through searches of PubMed, Scopus, Web of Science, and Google Scholar, covering studies published up to March 2026 on CBD, NLC, intranasal drug delivery, DS, and LGS.There is a dire need to carry out properly designed clinical trials that would demonstrate the safety, pharmacokinetics (PK) and efficacy of intranasal NLC-CBD in DS and LGS. The first pediatric clinical trials, adaptive trial models and regulatory harmonization are necessary to convert this noble nanomedicine approach into a clinical therapy. Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are rare and severe forms of epilepsy which often start in childhood. A significant number of patients fail to respond to several antiseizure drugs, and have recurrent seizures. Cannabidiol (CBD) is a chemical found in the cannabis plant that is effective in reducing seizures, but there are some limitations in oral CBD products, including slow absorption and inconsistent efficacy and the possibility for drug interaction. In this review, a novel delivery system of delivering CBD to the brain via a nose spray containing nanostructured lipid carriers (NLCs) is investigated. The use of these tiny lipid-based particles can aid in the delivery of CBD to the brain more rapidly and effectively, avoiding the digestion process and lowering first-pass metabolism. Consequently, intranasal NLC-CBD is likely to have a quicker onset of effect, better brain penetration, and reduced doses. This review provides a summary of existing preclinical evidence, as well as safety and regulatory considerations and outlines the possible clinical development options for this technology. It also underscores some of the future possibilities, such as the application of artificial intelligence (AI), novel clinical trial designs, and combination therapies. While additional clinical trials are necessary, intranasal NLC-CBD is a promising approach for better seizure control, quality of life and treatment ease for DS and LGS patients and their caregivers. **Primary Source & Scope:** Published in *Therapeutic delivery* (2026Sep17) conducted by Yashika, Sachin Yadav, Anish Arora, Nisha Bharti et al. [Primary Source Link](https://pubmed.ncbi.nlm.nih.gov/42751849/) | **Primary Record:** DOI: 10.1080/20415990.2026.2731738 | PMID: 42751849 How Strong Is This Evidence? The evidence base is scientifically plausible but clinically preliminary because the article is a narrative review rather than a randomized trial or meta-analysis. Its strength lies in integrating formulation science, nose-to-brain delivery concepts, and preclinical seizure model findings. Its statistical rigor is limited by the absence of pooled effect sizes, standardized animal model comparisons, pediatric pharmacokinetic data, or human DS and LGS outcomes. Where This Paper Deserves Skepticism Animal seizure models, including pentylenetetrazol-induced convulsions, do not fully reproduce the genetic, developmental, and network biology of Dravet syndrome or Lennox Gastaut syndrome. Publication bias may favor positive nanocarrier studies, while failed formulations, irritation data, device variability, and long-term pediatric nasal safety may be underreported. The review also cannot determine whether higher brain-to-plasma ratios translate into better seizure control or fewer adverse events in children. What This Paper Does Not Show This study does not prove that intranasal NLC-CBD reduces seizure frequency in children with Dravet syndrome or Lennox Gastaut syndrome. It also does not establish an approved dose, a rescue seizure indication, superiority over oral prescription CBD, or regulatory readiness for pediatric clinical use. How This Fits With the Broader Clinical Conversation Clinical research into Nanostructured lipid carriers for intranasal canna is progressing through rigorously documented peer-reviewed cohorts. Evaluating primary evidence enables clinicians to tailor care plans while respecting therapeutic boundaries. Dr. Caplan’s Take *The paper addresses a genuine clinical pain point: children with Dravet syndrome and Lennox Gastaut syndrome often remain burdened by seizures despite multidrug therapy, and oral CBD, while evidence based, is pharmacologically imperfect. A nose-to-brain delivery system is attractive because it could theoretically raise central nervous system exposure faster while lowering gastrointestinal and hepatic exposure, which may matter for sedation, appetite effects, diarrhea, transaminase elevation, and interactions with clobazam or valproate.* *The clinical translation bar, however, is high. Pediatric epilepsy care cannot rely on formulation elegance alone. Before this becomes meaningful for families, investigators need dose-ranging pharmacokinetic studies, nasal mucosa tolerability data, device reproducibility testing, age-stratified pediatric modeling, and randomized trials using seizure frequency, rescue medication use, caregiver burden, cognition, sleep, adverse events, and antiseizure drug interactions as endpoints.* What a Careful Reader Should Take Away Intranasal nanostructured lipid CBD is an intriguing research pathway, not a treatment recommendation today. Families should discuss any CBD formulation changes with a pediatric neurologist, especially when clobazam, valproate, sedation, liver enzymes, or feeding issues are involved. Evidence Interpretation Guide Table of Contents - [How to Interpret This Clinical Study](#How_to_Interpret_This_Clinical_Study)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Clinical Viewpoints](#CED_Perspective_Lens_Eight_Clinical_Viewpoints)[Clinical Evidence Synthesis](#Clinical_Evidence_Synthesis) - [Patient Communication](#Patient_Communication) - [Dosing & Formulations](#Dosing_Formulations) - [Safety & Side Effect Profile](#Safety_Side_Effect_Profile) - [Regulatory & Policy Dynamics](#Regulatory_Policy_Dynamics) - [Mechanisms & Physiology](#Mechanisms_Physiology) - [Research Limitations](#Research_Limitations) - [Future Outlook](#Future_Outlook) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Interpret This Clinical Study Navigating biomedical publications regarding Nanostructured lipid carriers for intranasal requires reviewing study methodology and patient eligibility. ### Three Rules for Critical Reading **Critical Rule**Separate oral CBD evidence from intranasal NLC-CBD evidence, because the approved route and the proposed route have different pharmacokinetics and safety questions. **Critical Rule**Treat animal seizure protection as hypothesis-generating, especially because PTZ models do not fully replicate DS or LGS genetics, development, or mixed seizure types. **Critical Rule**Look for future trials that report pediatric pharmacokinetics, seizure endpoints, adverse events, liver enzymes, drug interactions, and device reliability, not just brain delivery claims. Key Evaluation Question Does intranasal NLC-CBD improve clinically meaningful seizure outcomes in children compared with optimized oral CBD or standard adjunctive therapy? The Patient Question Should my child’s current CBD or antiseizure regimen be adjusted, and are there any legitimate trials of intranasal CBD that fit our diagnosis and safety profile? The Bottom Line This is a promising formulation review that identifies a rational next step for CBD delivery research, but it does not yet change clinical care for DS or LGS. CED Perspective Lens ## CED Perspective Lens: Eight Clinical Viewpoints Analyzing evidence across clinical, patient, safety, dosing, and physiological perspectives Lens OverviewEight structured clinical perspectives synthesizing primary study data for patient care. #### Clinical Evidence Synthesis The review gathers formulation, animal, and epilepsy literature to argue that intranasal nanostructured lipid carriers could improve CBD delivery to the brain. Its strongest evidence is pharmacologic plausibility and preclinical seizure protection, not pediatric clinical efficacy. For DS and LGS, oral prescription CBD already has human randomized trial support. This paper asks whether a different delivery route might solve absorption and systemic exposure problems, but no completed child trial answers that question yet. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayThe concept is promising, but human DS and LGS trial data are still missing. #### Patient Communication Families may hear the phrase nose-to-brain CBD and assume a faster, safer, more effective therapy is imminent. Clinicians should clarify that this is a proposed delivery platform, not an available standard of care for childhood epilepsy. The compassionate message is that researchers are trying to improve CBD treatment burden. The practical message is equally important: do not alter prescribed CBD, clobazam, valproate, or rescue plans without the epilepsy team. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayHope is appropriate, but treatment changes require neurologist-guided safety planning. #### Dosing & Formulations Intranasal NLC-CBD cannot be dose-converted directly from oral CBD. Nose-to-brain transport, nasal retention, droplet size, lipid composition, mucociliary clearance, and swallowed fraction can all change exposure. A future product would need pediatric pharmacokinetic studies measuring plasma CBD, central exposure surrogates, active metabolites, and interactions with existing antiseizure medications. Until then, practical dosing remains undefined. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayNo validated intranasal pediatric CBD dose exists for DS or LGS. #### Safety & Side Effect Profile Oral CBD safety concerns include somnolence, diarrhea, appetite change, weight effects, transaminase elevations, and drug interactions. Intranasal delivery might reduce some systemic exposure, but that remains an unproven clinical assumption. Nasal formulations introduce different questions: mucosal irritation, epistaxis, smell changes, aspiration risk, excipient tolerability, infection concerns, and long-term effects on developing pediatric nasal tissue. These require formal study. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayA new route may reduce some risks while creating others. #### Regulatory & Policy Dynamics Regulators will likely view intranasal NLC-CBD as a drug-device formulation, not merely a cannabinoid product. That means manufacturing consistency, sterility, particle characterization, device performance, and pediatric safety data all matter. Access should not precede evidence in fragile pediatric epilepsy populations. Compassionate use pathways may eventually appear, but routine clinical adoption should follow controlled pharmacokinetic, safety, and efficacy trials. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayRegulatory approval will require far more than promising animal seizure data. #### Mechanisms & Physiology The proposed advantage is partly anatomical. Intranasal delivery may exploit olfactory and trigeminal pathways, potentially allowing some drug to reach the central nervous system while bypassing first-pass hepatic metabolism. Nanostructured lipid carriers can improve solubility, protect CBD from degradation, and influence tissue distribution. Still, pediatric nasal physiology varies by age, inflammation, congestion, and administration technique. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayBiology supports the concept, but real children introduce major variability. #### Research Limitations The review does not provide pooled statistics, risk ratios, or human seizure reduction outcomes. It synthesizes a field where methods, formulations, animal models, endpoints, and measurement techniques may vary substantially. A pentylenetetrazol model can demonstrate anticonvulsant signal, but DS and LGS are complex developmental epileptic encephalopathies. Translation needs disease-relevant models and pediatric trials with clinically meaningful endpoints. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayPreclinical seizure protection is not the same as clinical syndrome control. #### Future Outlook The most useful next studies would be staged: formulation stability, juvenile animal safety, disease-specific models, adult tolerability, pediatric pharmacokinetics, then randomized DS and LGS efficacy trials. If successful, this approach could eventually support lower CBD doses, faster onset, or fewer systemic effects. That future depends on disciplined development rather than premature clinical enthusiasm. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayThe pathway is credible, but the decisive evidence must come from trials. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Intranasal+CBD+Nanocarriers+for+Dravet+and+Lennox+Gastaut+Syndromes&url=https%3A%2F%2Fcedclinic.com%2Fced-intranasal-cbd-nanocarriers-for-dra-2026-09-21%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-intranasal-cbd-nanocarriers-for-dra-2026-09-21%2F) [BlueSky](https://bsky.app/intent/compose?text=Intranasal+CBD+Nanocarriers+for+Dravet+and+Lennox+Gastaut+Syndromes%20https%3A%2F%2Fcedclinic.com%2Fced-intranasal-cbd-nanocarriers-for-dra-2026-09-21%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Source: Nanostructured lipid carriers for intranasal cannabidiol delivery in Dravet and Lennox-Gastaut syndromes: bridging preclinical promise to clinical translation.](https://pubmed.ncbi.nlm.nih.gov/42751849/) Related Reading at CED ClinicContinue exploring the evidence[CED Clinic Medical Cannabis Education](https://cedclinic.com/about-us/education/) Explore clinical guides, dosing frameworks, and patient resources from Dr. Caplan. [Read Clinical Resources](https://cedclinic.com/about-us/education/)[Understanding Cannabis Dosing and Ratios](https://cedclinic.com/topic-dosage/) A clinical overview of cannabinoid titration and administration methods for patient care. [View Dosing Guide](https://cedclinic.com/topic-dosage/)[Latest Medical Science and Research Reviews](https://cedclinic.com/category/cannabis-science/) Browse CED Clinic’s archive of peer-reviewed study deep dives. [Browse Science Archive](https://cedclinic.com/category/cannabis-science/) ## Frequently Asked Questions Is intranasal NLC-CBD approved for Dravet syndrome or Lennox Gastaut syndrome? No. The reviewed paper describes a proposed and preclinical delivery strategy. It does not report an approved intranasal CBD product for DS or LGS, and it does not provide pediatric efficacy or dosing data. How is this different from oral prescription CBD? Oral prescription CBD is swallowed, absorbed through the gastrointestinal tract, and affected by first-pass metabolism and food. Intranasal NLC-CBD is designed to improve nasal absorption and possible brain targeting, but that advantage remains unproven in children. Could this work faster than oral CBD? Possibly, based on the delivery concept and preclinical pharmacology. However, the review does not provide human onset-of-action data, and it should not be considered a proven rescue treatment for acute seizures. Can families make or use compounded intranasal CBD now? Families should not attempt this outside a regulated clinical trial or specialist-supervised setting. Nasal formulations require careful control of sterility, particle size, excipients, concentration, spray volume, and mucosal tolerability. Does this reduce interactions with clobazam or valproate? It might reduce systemic exposure in theory, but this has not been proven clinically. Any CBD formulation can potentially interact with antiseizure medications, so sedation, liver enzymes, and drug levels may still require monitoring. What endpoints should future trials measure? Future trials should measure convulsive seizure frequency, drop seizures where relevant, responder rates, rescue medication use, caregiver burden, sleep, cognition, quality of life, adverse events, liver enzymes, and drug-drug interactions. Why are Dravet syndrome and Lennox Gastaut syndrome so difficult to study? They are rare, heterogeneous, developmentally complex epileptic encephalopathies with multiple seizure types and heavy background medication use. Small populations, fluctuating seizure patterns, and developmental comorbidities make trial design challenging. Does higher brain CBD exposure guarantee better seizure control? No. Higher brain targeting is pharmacologically encouraging, but seizure outcomes depend on dose-response relationships, receptor and network effects, tolerability, background therapies, and syndrome-specific biology. What safety issues are specific to intranasal delivery? Key concerns include nasal irritation, bleeding, congestion effects, smell disturbance, aspiration risk, excipient sensitivity, infection control, dosing inconsistency, and unknown long-term effects on pediatric nasal mucosa. What should patients ask their neurologist today? Ask whether current CBD therapy is optimized, whether interactions with clobazam or valproate are being monitored, whether liver enzymes should be checked, and whether any legitimate clinical trials are available. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).